^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Basal Cell Carcinoma
    Drug:Elyxyb (celecoxib) (COX2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    Source:
    NCCN
    Published date:
    07/14/2020
    Excerpt:
    ...NCCN panel does not recommend celecoxib for prevention of actinic keratoses, cSCC or BCC.